In a significant advancement for prostate cancer research, a first-of-its-kind study led by Emory researchers uncovered how ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key ...

Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to a 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and Entresto ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months ...